Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.

Publication Type:

Journal Article


Blood, Volume 111, Issue 4, p.2261-8 (2008)


2008, Animals, Antibody Development Core Facility, Antigens, CD45, Biologics Production Core Facility, Center-Authored Paper, Clinical Research Division, Comparative Medicine Core Facility, Disease Models, Animal, Female, Flow Cytometry Core Facility, Iodine Radioisotopes, Leukemia, Myeloid, Acute, MICE, Mice, Inbred Strains, Radioimmunotherapy, Shared Resources


We describe the use of pretargeted radioimmunotherapy (PRIT) using an anti-murine CD45 antibody-streptavidin (SA) conjugate followed by radiobiotin to deliver radiation selectively to murine hematolymphoid tissues, which may potentially augment the efficacy and decrease the toxicity of radioimmunotherapy for disseminated murine leukemia. Biodistribution and therapeutic results demonstrated high target organ to nontarget organ ratios of radioactivity and significant long-term survival in leukemic mice using PRIT. These data suggest that anti-CD45 PRIT using an anti-CD45-SA conjugate in a syngeneic murine model of disseminated leukemia may be more effective and less toxic than directly labeled monoclonal antibodies.